Latest Global Markets News

Zelira Therapeutics has locked in a $650,000 loan facility secured against its anticipated FY25 R&D tax rebate, aiming to accelerate its HOPE SPV clinical trial and strengthen working capital.

Macquarie Group Limited reported a 5% increase in FY25 profit to A$3.715 billion, declaring a higher dividend and announcing a key CFO transition. The group also outlined a strategic divestment and cautious outlook for FY26.

Macquarie Group reported a decline in net profit contribution for the first quarter of FY26, driven by mixed performances across its divisions, while maintaining a robust capital surplus and announcing a key CFO transition.

Fortescue Metals Group delivered record iron ore shipments in FY25 alongside a rare cost decline, while recalibrating its green energy ambitions and maintaining a strong financial position.

Paladin Energy reports a 33% production surge at its Langer Heinrich Mine alongside a key environmental milestone for its Canadian project and announces a new CEO appointment. The company outlines strong FY2026 guidance amid ongoing operational ramp-up.

Adherium Limited has appointed seasoned medtech executive Dawn Bitz as CEO to spearhead the expansion of its Hailie® respiratory monitoring platform, with a strong focus on the US market.

WAM Global Limited outperformed the MSCI World Index with a 19.4% portfolio gain in FY2025, prompting an increased fully franked dividend of 17.0 cents per share. The company’s strong results reflect strategic positioning amid global market volatility.

Green Critical Minerals has commissioned its first VHD Graphite production module and secured $7 million to drive commercialisation, while its McIntosh Project delivers robust economic metrics.

Kingsland Minerals is finalising its scoping study for the Leliyn Graphite Project, positioning itself to capitalise on shifting global graphite markets driven by new US tariffs on Chinese imports.

Microba Life Sciences reports record Q4 FY25 microbiome test sales in Australia and the UK, underpinned by landmark clinical studies and a $14.5 million capital raise. The company is transitioning away from legacy products to focus on high-value diagnostics, positioning for sustained growth in FY26.

Larvotto Resources has successfully raised US$105 million through a senior secured bond to fund the restart of its Hillgrove Gold-Antimony Project in New South Wales, targeting mining operations by mid-2026.

EVE Health Group has secured regulatory approval enabling prescription access for its lead products Libbo and Dyspro in Australia, setting the stage for a commercial rollout before the end of 2025.